TNO, Mitsubishi Pharma Enter siRNA Target Validation Pact

genomeweb
360dx

TNO, Mitsubishi Pharma Enter siRNA Target Validation Pact

Sep 06, 2005

NEW YORK, Sept. 6 (GenomeWeb News) - Dutch biotech TNO and Mitsubishi Pharma of Japan have entered into a technology development collaboration for siRNA-based target validation studies.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

NIH All of Us Program Awards $28.6M to Three Genome Centers Led by Baylor, Broad, UW
Aperiomics Wins $229K NSF Award for Metagenomic Sequencing-Based Pathogen ID Tech
Tourette Disorder Risk Genes, Pathways Emerge From Expanded Trio Analysis
IQuity Wins $320K NIH Grant to Develop Alzheimer's Diagnostic Tech
Genome of Medieval Relapsing Fever Pathogen Provides Insights Into Microbe's Evolution
GeneCentric Licenses UNC Pancreatic Cancer Subtyping Tech

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Main menu